The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Correlation of Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231 With Rates of Hippocampal Atrophy in Alzheimer Disease
Abstract
Background The microtubule-associated tau protein abnormally phosphorylated at threonine 231 (p-tau231) has been investigated as a potential marker of Alzheimer disease. Levels of cerebrospinal fluid (CSF) p-tau231 vary across patients with Alzheimer disease. We hypothesized that these variations partially reflect differences in the degree of neuronal damage and therefore may be used to predict structural disease progression. Objective To investigate whether CSF p-tau231 levels correlate with rates of hippocampal atrophy as an in vivo marker of regional neuronal loss. Design and patients We measured hippocampal volumes on the basis of serial magnetic resonance image examinations in 22 patients with Alzheimer disease. In addition, we determined CSF p-tau231 levels at baseline. Results Levels of CSF p-tau231 were significantly correlated with baseline hippocampal volumes (P Conclusion These findings suggest that variations in p-tau231 levels may be used to predict progression of brain atrophy in patients with Alzheimer disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The same study has also reported, no significant effect of T-tau level on hippocampal atrophy (Hampel et al., 2005).”
From T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease (2015) · cites this paper as Hampel et al., 2005
In the citing paper
“It has been shown that the increased CSF tau level corresponds to the higher baseline hippocampal volume in AD.”
From T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease (2015) · cites this paper as Hampel et al., 2005
Citations
Cites
Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space
Collins, D. L., Neelin, P., Peters, T. M., & Evans, A. C. (1994) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199403000-00005 · Cited by 3,431 · cited 1×
“Before volumetric measurements, a transformation algorithm was used to align MRIs between time points.(11) First, for each patient the second (and for 2 patients, the third) MRI was aligned to the first MRI in the series using a 6-parameter rigid body transformation.”
MethodSelf-citationAugustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD
Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937
Cited by
Sorted by citations
Items 101–155 of 155
An overview of biomarkers in Alzheimer′s disease
Mathuranath, P. S., & Wattamwar, P. R. (2010) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.74256 · Cited by 28
Post-Translational Modifications in Alzheimer's Disease and the Potential for New Biomarkers
Russell, C. L., Končarević, S., & Ward, M. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132312 · Cited by 26
“could be suitable markers of disease progression [27].”
Proteomic Analysis of Protein Phosphorylation and Ubiquitination in Alzheimer’s Disease
Thomas, S. N., Cripps, D., & Yang, A. J. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-562-6_8 · Cited by 24
“A distinct hierarchical pattern of tau phosphorylation has been shown to correlate with the progression of AD neuropathology (14, 15).”
BackgroundSantos, J. R. F., Bauer, C., Schuchhardt, J., Wedekind, D., Waniek, K., Lachmann, I., Wiltfang, J., & Vogelgsang, J. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01982-5 · Cited by 26
Biological markers of Alzheimer?s disease
de Souza, L. C., Sarazin, M., Teixeira, A. L., Caramelli, P., dos Santos, A. M., & Dubois, B. (2014) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20130233 · Cited by 33
“Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.”
MethodLi, Z., Fan, Z., & Zhang, Q. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230799 · Cited by 27
Clinical investigations in primary care.
de Souza, L. D., Sarazin, M., Goetz, C., & Dubois, B. (2009) · Monographs in neural sciences · doi:10.1159/000197897 · Cited by 21
Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau
Li, D., Wang, L., Maziuk, B. F., Yao, X., Wolozin, B. L., & Cho, Y. K. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003557 · Cited by 20
“In addition, levels of pThr-231 in the CSF were correlated with rates of hippocampal atrophy in AD patients (67).”
BackgroundPérez, M., Medina, M., Hernández, F., & Ávila, J. (2018) · BioMolecular Concepts · doi:10.1515/bmc-2018-0001 · Cited by 20
“The amount of phosphorylated Tau in the CSF has been measured (54) and an increase in phosphorylation at T181 (88) or T231 (89) has been described in AD patients.”
BackgroundArastoo, M., Lofthouse, R. A., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228673 · Cited by 21
“Other potential AD biomarkers such as Ptau231 [76] and P-tau199 [77] have been studied but not to the same degree as the “gold standard” PFigure 3.”
ResultNeuroAiD® (MLC601) and Amyloid Precursor Protein Processing
Lim, Y.-A., Murray, L. A., Lai, M. K. P., & Chen, C. (2013) · Cerebrovascular Diseases · doi:10.1159/000346236 · Cited by 12
New Tools for the Study of Alzheimer’s Disease
Fjell, A. M., & Walhovd, K. B. (2011) · The Neuroscientist · doi:10.1177/1073858410392586 · Cited by 17
Wied, C. C. G., Kritsidima, M., & Elferink, A. J. A. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0049-2 · Cited by 16
Maldonado, H., Ortiz-Riaño, E., Krause, B. J., Barriga, A., MEDINA, F., Pando, M. E., Alberti, C., Kettlun, A. M., Collados, L., Garcı́a, L., et al. (2008) · Biological Research · doi:10.4067/s0716-97602008000300001 · Cited by 14
“However, in CSF of HAM/TSP, the tau isoform of 52 kDa was similarly phosphorylated, as in controls in these residues (Table II) (Van Everbroeck et al., 2002; Hampel et al., 2005; Buerger et al., 2006; Sengupta et al. , 2006a¸b).”
BackgroundThe role of peripheral fatty acids as biomarkers for Alzheimer's disease and brain inflammation
Cisbani, G., & Bazinet, R. P. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102205 · Cited by 14
Tau-Proteins as Gender-Specific State Markers in Amnestic Mild Cognitive Impairment
Riepe, M. W., Karl, J., Tumani, H., & Arnim, C. A. F. V. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318738 · Cited by 14
“However, at present these biomarkers are not considered to be sensitive markers of disease progression [”
BackgroundAn, N., Fu, Y., Shi, J., Guo, H., Yang, Z., Li, Y., Li, S., Wang, Y., Yao, Z.-J., & Hu, B. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201162 · Cited by 13
“The volume loss of the hippocampus and amygdala in non-demented individuals has been reported to increase the risk of developing AD [38, 39] and to be associated with higher cerebrospinal fluid tau level (a hallmark of AD pathology) [86–88].”
Edsbagge, M., Andreasson, U., Ambarki, K., Wikkelsø, C., Eklund, A., Blennow, K., Zetterberg, H., & Tullberg, M. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161257 · Cited by 17
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 33
“T-tau and p-tau concentrations in the CSF have been associated with NFT load at autopsy (Buerger et al., 2006a; Tapiola et al., 2009), as well as with cognitive decline and brain atrophy (Buerger et al., 2002; Hampel et al., 2005; Fjell et al., 2010; Vemuri et al., 2010b).”
BackgroundWang, H., Ma, L., Sheng, Z.-H., Liu, J.-Y., Yuan, W.-Y., Guo, F., Zhang, W., & Tan, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1256389 · Cited by 13
Thomas, S. N., & Yang, A. J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6598-4_10 · Cited by 15
Lu, K. P., & Zhou, X. Z. (2024) · Science Signaling · doi:10.1126/scisignal.adi8743 · Cited by 12
“…in AD ( 214 – 216 ), and its amounts correlate with cognitive decline in patients with mild cognitive impairment and AD ( 217 ), with neocortical tangle accumulation ( 218 ), and with hippocampal atrophy rate ( 219 ) and predict the progression from mild cognitive impairment to AD ( 220 , 221 ).”
BackgroundClinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
Caraci, F., Bosco, P., Leggio, G. M., Malaguarnera, M., Drago, F., Bucolo, C., & Salomone, S. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990141 · Cited by 12
Challenges in the development of companion diagnostics for neuropsychiatric disorders
Nikolcheva, T., Jäger, S., Bush, T. A., & Vargas, G. A. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.67 · Cited by 10
Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias
Llorens, F., Villar‐Piqué, A., Candelise, N., Ferrer, I., & Zerr, I. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73528 · Cited by 10
“In contrast, p-tau-231 levels correlate with the rate of hippocampal atrophy in AD cases, which are independent of disease duration and severity [93] as well as with a reduction hippocampal volume detected by magnetic”
BackgroundGranadillo, E. D., Paholpak, P., Mendez, M. F., & Teng, E. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477718 · Cited by 13
Zhang, Y., Londos, E., Minthon, L., Wattmo, C., Blennow, K., Liu, H. J., Bronge, L., Aspelin, P., & Wahlund, L. (2009) · Acta Radiologica · doi:10.1080/02841850902912028 · Cited by 8
Kognitive Störungen: Koma, Delir, Demenz
Förstl, H. (2006) · Springer eBooks · doi:10.1007/3-540-30887-3_5 · Cited by 8
Adeyemi, O. F., Gowland, P. A., Bowtell, R. W., Mougin, O. E., & Hosseini, A. A. (2025) · European Journal of Neurology · doi:10.1111/ene.70076 · Cited by 7
“Appendix A”
López‐Cuevas, R., Baquero‐Toledo, M., Cuevas-Jiménez, A., Martín-Ibáñez, N., Pascual-Costa, R., Moreno-Monedero, M. J., Martínez, A. J. C., Peña‐Bautista, C., Ferrer, I., Álvarez-Sánchez, L., et al. (2023) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.07.024 · Cited by 3
Clinical gene therapy development for the central nervous system: Candidates and challenges for AAVs
Leong, T. W., Pal, A., Cai, Q., Gao, Z., Li, X., Bleris, L. G., Hayenga, H. N., & Qin, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.009 · Cited by 7
LRP::FLAG Reduces Phosphorylated Tau Levels in Alzheimer’s Disease Cell Culture Models
Cuttler, K., Bignoux, M. J., Otgaar, T. C., Chigumba, S., Ferreira, E., & Weiss, S. F. T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200244 · Cited by 6
“Indeed, studies have shown that the degree of dementia is correlated with the number of neurofibrillary tangles present within the brain tissue [10–14].”
Biomarker identification for diagnosis of Alzheimer's disease
Pelech, S. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2.5.577 · Cited by 6
Cerebrospinal Fluid Biomarkers for Mild Cognitive Impairment
Bryś, M., Mosconi, L., Santi, S. D., Rich, K. E., & de Leon, M. J. (2006) · Aging Health · doi:10.2217/1745509x.2.1.111 · Cited by 5
Advances and emerging challenges in detecting Tau proteoforms for Alzheimer's disease diagnosis
Cai, Q., Miao, M., & Li, Z. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.118897 · Cited by 3
P-tau231 as a Diagnostic Biomarker for Alzheimer's Disease and Mild Cognitive Impairment
Nabizadeh, F., Salehi, N., Ramezannezhad, E., Sadeghmousavi, S., & Khalili, E. (2022) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_77_22 · Cited by 6
Delacourte, A., Campion, D., & Davous, P. (2007) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(07)44093-3 · Cited by 23
The Methodology of Neuroproteomics
Ottens, A. K. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-562-6_1 · Cited by 4
Sindi, G., Ismael, S., Uddin, R., Slepchenko, K. G., Colvin, R. A., & Lee, D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.02.597022 · Cited by 3
“It is interesting to note that some of these pSites are also phosphorylated in tau in the cerebrospinal fluid (CSF) of AD brains (Hampel et al, 2005; Suárez Calvet et al, 2020; Janelidze et al., 2020; Ashton et al, 2022).”
BackgroundVers un diagnostic biologique de la maladie d’Alzheimer et des syndromes apparentés
Krolak‐Salmon, P., Seguin, J., Perret‐Liaudet, A., Desestret, V., Vighetto, A., & Bonnefoy, M. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.01.029 · Cited by 8
Ersmark, I., L, O., E., S., I, B., R, B., A, S., Lister, A., Cahill, J., Fulton, E., & Shapiro (1995) · 2012 14th International Conference on Megagauss Magnetic Field Generation and Related Topics (MEGAGAUSS) · doi:10.1080/000164702753671579 · Cited by 3
López‐Cuevas, R., Baquero‐Toledo, M., Cuevas-Jiménez, A., Martín-Ibáñez, N., Pascual-Costa, R., Moreno-Monedero, M. J., Martínez, A. J. C., Peña‐Bautista, C., Ferrer, I., Álvarez-Sánchez, L., et al. (2020) · Neurología · doi:10.1016/j.nrl.2020.07.026 · Cited by 3
Paltseva, E. M., Zuev, V. A., Kozhevnikova, E. O., Linkova, N. S., Kvetnaia, T. V., Polyakova, V. O., & Kvetnoy, I. M. (2018) · Advances in Gerontology · doi:10.1134/s2079057018020133 · Cited by 2
Neurobiologische Frühdiagnostik der Alzheimer-Krankheit
Hampel, H. J., Teipel, S., & Bürger, K. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2317-x · Cited by 4
Self-citation[What use of biological markers for the diagnosis of Alzheimer's disease and associated disorders?].
Krolak-Salmon, P. (2010) · Psychologie and NeuroPsychiatrie du Vieillissement · doi:10.1684/pnv.2009.0189 · Cited by 2
“Une relation inversement proportionnelle entre la concentration de la ptau231 dans le LCR et le volume de l’hippocampe a été démontrée dans la MA [55].”
BackgroundGlia inflammation and cell death pathways drive disease progression in preclinical and early AD
Woo, M. S., Therriault, J., Hosseini, S. A., Wang, Y.-T., Macedo, A. C., Rahmouni, N., Aumont, É., Servaes, S., Tissot, C., Arias, J. F., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00316-1 · Cited by 5
“Thus, our data provide evidence that disease progression in early AD is driven by activation of CDPs that results in glia activation and neuroin fl ammation, which subsequently lead to further ( A ) Heatmap of Spearman correlation coef fi cients of all measured proteins (y-axis) and hippocampal…”
Linking evidence for targeted blood biomarkers in post-stroke cognitive impairment and dementia
Hong, J., Mun, K. T., Kern, K. C., Thirion, M. L., & Hinman, J. D. (2025) · Frontiers in Stroke · doi:10.3389/fstro.2024.1491542 · Cited by 1
Jacob, A. (2014) · Cureus · doi:10.7759/cureus.177
“Biomolecular techniques include CSF measures of a reduced amyloid beta concentration, increased total concentration of tau protein, and increased phospotau [10-13].”
MethodLes marqueurs biochimiques du LCR : un outil diagnostique de la maladie d’Alzheimer
Schraen‐Maschke, S., Crinquette, C., Bombois, S., Pasquier, F., Delacourte, A., Buée, L., & Sablonnière, B. (2007) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/s1627-4830(07)89957-0
Biomarqueurs du liquide cérébrospinal dans la maladie d’Alzheimer
Bombois, S., Pasquier, F., Sablonnière, B., Buée, L., & Schraen‐Maschke, S. (2013) · Springer eBooks · doi:10.1007/978-2-8178-0443-9_2
Cdk5 as a Drug Target for Alzheimer’s Disease
Lau, L., & Hicks, C. D. (2008) · Springer eBooks · doi:10.1007/978-0-387-78887-6_18 · Cited by 2
Bétard, C., Boneschi, F. M., & Caramelli, P. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse237
Research and Prospect of Blood Biomarkers for Alzheimer’s Disease
蓝, 萍. (2023) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2023.131002
Molecular Marker and Therapeutic Regimen for Neurodegenerative Diseases
Dey, S., Rai, N., Shekhar, S., Singh, A. P., & Agnihotri, V. (2019) · Springer eBooks · doi:10.1007/978-981-13-3585-3_2
Delacourte, A., Campion, D., & Davous, P. (2007) · EMC - Neurologia · doi:10.1016/s1634-7072(07)70544-5 · Cited by 1
Metadata
- Authors
- Hampel, H., Bürger, K., Pruessner, J. C., Zinkowski, R., DeBernardis, J., Kerkman, D., Leinsinger, G., Evans, A. C., Davies, P., Möller, H.-J., & Teipel, S. J.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- ORCID
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2005-05-01
- Volume
- 62
- Issue
- 5
- Pages
- 770
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2032332012
- Cited by
- 175
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 8 · 2015: 8 · 2014: 10 · 2013: 10 · 2012: 10
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- tau phosphorylation, cerebrospinal fluid biomarkers, hippocampal atrophy, hippocampal volume, Alzheimer's disease, disease progression, neuronal loss, magnetic resonance imaging
- MeSH terms
- Aged, Alzheimer Disease, Atrophy, Enzyme-Linked Immunosorbent Assay, Female, Hippocampus, Humans, Functional Laterality, Magnetic Resonance Imaging, Male, Mental Status Schedule, Middle Aged, Phosphorylation, Statistics as Topic, Threonine, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
